1. Scrip
  2. >>Archive

Once Sluggish Sleep Apnea Gets Active

 
• By Mary Stuart

The past year was a busy one in the sleep apnea sector of the respiratory market. All three major segments of the sleep apnea market--sleep testing equipment, continuous positive airway pressure (CPAP) devices, and therapeutic implants--were represented by the year's deals, which include four acquisitions and two venture financings, and we're not even counting the $4.9 billion acquisition of Respironics by Philips, which was announced at the tail end of 2007.

The past year was a busy one in the sleep apnea sector of the respiratory market. All three major segments of the sleep apnea market--sleep testing equipment, continuous positive airway pressure (CPAP) devices, and therapeutic implants--were represented by the year’s deals, which include four acquisitions and two venture financings, and we’re not even counting the $4.9 billion acquisition of Philips Respironics by Royal Philips Electronics NV, which was announced at the tail end of 2007. [See Deal]

Obstructive sleep apnea (OSA) is increasingly identified as a disorder that should absolutely be treated in its moderate to severe...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Stock Watch: On Q1 Vaccine Sales And Measles Outbreaks

 
• By Andy Smith

A recent study suggested that measles could become endemic in the US due to low vaccination rates. However, first-quarter vaccine sales offered a more nuanced picture.

Merck & Co.’s RSV Antibody Approved In US In Time To Compete With Blockbuster Beyfortus

 
• By Mandy Jackson

The US FDA approved Merck’s Enflonsia (clesrovimab) to prevent RSV in newborns and infants on the same day Sanofi assured that it would ship Beyfortus in time for the 2025-2026 RSV season.

Metsera’s Amylin Analog Stars In Obesity Phase I

 
• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.